ValuEngine cut shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) from a hold rating to a sell rating in a research note released on Thursday.
Several other research firms have also commented on KERX. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $8.75 price objective for the company in a research note on Wednesday, July 12th. BidaskClub lowered Keryx Biopharmaceuticals from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Morgan Stanley restated an equal weight rating and issued a $7.00 price objective (up from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals and gave the stock a buy rating in a research note on Thursday, July 27th. Finally, Cowen and Company restated a market perform rating on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $7.48.
Keryx Biopharmaceuticals (NASDAQ KERX) opened at 6.95 on Thursday. Keryx Biopharmaceuticals has a 12 month low of $4.11 and a 12 month high of $8.38. The stock’s market capitalization is $825.31 million. The stock has a 50 day moving average price of $7.01 and a 200 day moving average price of $6.55.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.60). The company had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The company’s revenue for the quarter was up 62.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.42) earnings per share. On average, equities research analysts forecast that Keryx Biopharmaceuticals will post ($1.23) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Downgraded by ValuEngine” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://ledgergazette.com/2017/09/24/keryx-biopharmaceuticals-inc-kerx-downgraded-by-valuengine.html.
Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. increased its stake in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 590 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,628 shares in the last quarter. OZ Management LP purchased a new stake in Keryx Biopharmaceuticals in the 1st quarter worth $109,000. Jane Street Group LLC purchased a new stake in Keryx Biopharmaceuticals in the 1st quarter worth $141,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Keryx Biopharmaceuticals in the 2nd quarter worth $183,000. Institutional investors and hedge funds own 65.19% of the company’s stock.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.